Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?

The pandemics of coronavirus disease 2019 (COVID-19) and non-alcoholic fatty liver disease (NAFLD) coexist. Elevated liver function tests are frequent in COVID-19 and may influence liver damage in NAFLD, while preexisting liver damage from NAFLD may influence the course of COVID-19. However, the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietrich, Christoph G, Geier, Andreas, Merle, Uta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846932/
https://www.ncbi.nlm.nih.gov/pubmed/36687116
http://dx.doi.org/10.3748/wjg.v29.i2.367
_version_ 1784871312630480896
author Dietrich, Christoph G
Geier, Andreas
Merle, Uta
author_facet Dietrich, Christoph G
Geier, Andreas
Merle, Uta
author_sort Dietrich, Christoph G
collection PubMed
description The pandemics of coronavirus disease 2019 (COVID-19) and non-alcoholic fatty liver disease (NAFLD) coexist. Elevated liver function tests are frequent in COVID-19 and may influence liver damage in NAFLD, while preexisting liver damage from NAFLD may influence the course of COVID-19. However, the prognostic relevance of this interaction, though, is unclear. Obesity is a risk factor for the presence of NAFLD as well as a severe course of COVID-19. Cohort studies reveal conflicting results regarding the influence of NAFLD presence on COVID-19 illness severity. Striking molecular similarities of cytokine pathways in both diseases, including postacute sequelae of COVID-19, suggest common pathways for chronic low-activity inflammation. This review will summarize existing data regarding the interaction of both diseases and discuss possible mechanisms of the influence of one disease on the other.
format Online
Article
Text
id pubmed-9846932
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-98469322023-01-19 Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier? Dietrich, Christoph G Geier, Andreas Merle, Uta World J Gastroenterol Minireviews The pandemics of coronavirus disease 2019 (COVID-19) and non-alcoholic fatty liver disease (NAFLD) coexist. Elevated liver function tests are frequent in COVID-19 and may influence liver damage in NAFLD, while preexisting liver damage from NAFLD may influence the course of COVID-19. However, the prognostic relevance of this interaction, though, is unclear. Obesity is a risk factor for the presence of NAFLD as well as a severe course of COVID-19. Cohort studies reveal conflicting results regarding the influence of NAFLD presence on COVID-19 illness severity. Striking molecular similarities of cytokine pathways in both diseases, including postacute sequelae of COVID-19, suggest common pathways for chronic low-activity inflammation. This review will summarize existing data regarding the interaction of both diseases and discuss possible mechanisms of the influence of one disease on the other. Baishideng Publishing Group Inc 2023-01-14 2023-01-14 /pmc/articles/PMC9846932/ /pubmed/36687116 http://dx.doi.org/10.3748/wjg.v29.i2.367 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Dietrich, Christoph G
Geier, Andreas
Merle, Uta
Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
title Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
title_full Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
title_fullStr Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
title_full_unstemmed Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
title_short Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
title_sort non-alcoholic fatty liver disease and covid-19: harmless companions or disease intensifier?
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846932/
https://www.ncbi.nlm.nih.gov/pubmed/36687116
http://dx.doi.org/10.3748/wjg.v29.i2.367
work_keys_str_mv AT dietrichchristophg nonalcoholicfattyliverdiseaseandcovid19harmlesscompanionsordiseaseintensifier
AT geierandreas nonalcoholicfattyliverdiseaseandcovid19harmlesscompanionsordiseaseintensifier
AT merleuta nonalcoholicfattyliverdiseaseandcovid19harmlesscompanionsordiseaseintensifier

Ejemplares similares